| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/24/2003 | WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002058690A3 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | WO2002056875A3 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 04/24/2003 | WO2002047710A3 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer |
| 04/24/2003 | WO2002046383A3 Protein modification and maintenance molecules |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002043786B1 Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders |
| 04/24/2003 | WO2002026825A3 G-protein coupled receptors |
| 04/24/2003 | WO2002016615A3 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 04/24/2003 | WO2001077389A3 Genes expressed in foam cell differentiation |
| 04/24/2003 | US20030078438 N-heterocyclicamide compounds; used as anticoagulant agent |
| 04/24/2003 | US20030078435 Process for the synthesis of a known tetrazol derivative |
| 04/24/2003 | US20030078432 Novel benzotriazoles anti-inflammatory compounds |
| 04/24/2003 | US20030078431 Biheterocyclic compounds having high anticoagulant activity, used as inhibitors of factor Xa |
| 04/24/2003 | US20030078417 For protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents; for therapy of phospholipase mediated injury, injury due to oxidation, and inflammation |
| 04/24/2003 | US20030078376 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| 04/24/2003 | US20030078300 Fused bicyclic or tricyclic amino acids |
| 04/24/2003 | US20030078299 Anti-cancer nitro- and thia-fatty acids |
| 04/24/2003 | US20030078289 Indole carboxylic acids as thyroid receptor ligands |
| 04/24/2003 | US20030078288 Indole derivatives |
| 04/24/2003 | US20030078280 Macroheterocylic compounds useful as kinase inhibitors |
| 04/24/2003 | US20030078277 For therapy and prophylaxis of depression; Tourette syndrome, autism, bipolar disorder, cyclothymia, schizophrenia, Alzheimer disease, obesity, diabetes, alcohol dependence, sleep disorder, insomnia, migraine, stress headache, etc. |
| 04/24/2003 | US20030078276 Matrix metalloproteinase inhibitors |
| 04/24/2003 | US20030078275 For therapy of cancer, diabetes and Alzheimer's disease |
| 04/24/2003 | US20030078274 Method of reducing neuronal injury or apoptosis |
| 04/24/2003 | US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| 04/24/2003 | US20030078265 Inhibitors of nitric oxide synthase (nos) |
| 04/24/2003 | US20030078260 2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 04/24/2003 | US20030078259 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders |
| 04/24/2003 | US20030078258 Adrenergic blocking agents |
| 04/24/2003 | US20030078254 Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 04/24/2003 | US20030078239 Ketone compounds and compositions for cholesterol management and related uses |
| 04/24/2003 | US20030078234 Applying semi-crystalline acetylglucosamine polysaccharide for treating vasoconstriction, reduction in blood flow |
| 04/24/2003 | US20030078232 A stimulants for bone marrow cell proliferation, countering the toxic side effect of drugs, in particular chemotherapeutic drugs, such as leukopenia and neutropenia |
| 04/24/2003 | US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077810 CHAMP - a novel cardiac helicase-like factor |
| 04/24/2003 | US20030077802 Human PRL1 phosphatase |
| 04/24/2003 | US20030077734 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 04/24/2003 | US20030077705 Nucleotide sequences coding polypeptide for use in the treatment of inflammation and ischemia-reperfusion injury |
| 04/24/2003 | US20030077682 Arginine free composition for use in treatment of thrombsis |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077585 Nucleotide sequences coding polypeptide for use in the diagnosis, detection, prevention and treatment of bacterial infection |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077279 Methods for treating vascular disease by inhibiting toll-like receptor-4 |
| 04/24/2003 | US20030077271 Use of coagulation factor VII-activating protease for the prophylaxis and therapy of vasoproliferative disorders |
| 04/24/2003 | US20030077253 Implantable or insertable therapeutic agent delivery device |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | US20030077243 Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| 04/24/2003 | US20030075172 Method and apparatus for dispensing inhalator medicament |
| 04/24/2003 | CA2727642A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2463996A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | CA2463994A1 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
| 04/24/2003 | CA2463911A1 Tumor targeted photodiagnostic-phototherapeutic agents |
| 04/24/2003 | CA2463908A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | CA2463906A1 Pathological tissue detection and treatment employing targeted benzoindole optical agents |
| 04/24/2003 | CA2463850A1 Remodeling of tissues and organs |
| 04/24/2003 | CA2463816A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463724A1 Organosulfur inhibitors of tyrosine phosphatases |
| 04/24/2003 | CA2463686A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them |
| 04/24/2003 | CA2463685A1 Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 04/24/2003 | CA2463682A1 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | CA2463676A1 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/24/2003 | CA2463628A1 Himbacine analogues as thrombin receptor antagonists |
| 04/24/2003 | CA2463624A1 Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications |
| 04/24/2003 | CA2463579A1 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | CA2463518A1 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | CA2463473A1 Targeted therapeutic proteins |
| 04/24/2003 | CA2463469A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | CA2463426A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof |
| 04/24/2003 | CA2463395A1 Therapeutic agents for low hdl-cholesterolemia |
| 04/24/2003 | CA2463159A1 Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors |
| 04/24/2003 | CA2462980A1 Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2462588A1 Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof |
| 04/24/2003 | CA2462514A1 Dicarboxylic acid derivatives, their preparation and therapeutical use |
| 04/24/2003 | CA2462442A1 Alkyne matrix metalloproteinase inhibitors |
| 04/24/2003 | CA2462441A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| 04/24/2003 | CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | CA2461836A1 Detection and treatment of intravascular lesions |
| 04/24/2003 | CA2461550A1 Stabilized compositions of aqueous reduced coenzyme q solution |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461170A1 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/24/2003 | CA2458981A1 Combinations comprising cox-2 inhibitors and aspirin |
| 04/23/2003 | EP1304324A1 Serotonin reuptake inhibitors |
| 04/23/2003 | EP1304322A2 Carboxylic acid compound and use thereof |
| 04/23/2003 | EP1304123A2 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 04/23/2003 | EP1304108A2 Anti-arrhythmic composition and methods of treatment |
| 04/23/2003 | EP1304101A1 Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
| 04/23/2003 | EP1303620A2 Regulation of human desc1-like serine protease |
| 04/23/2003 | EP1303619A1 A novel human soluble secreted endopeptidase (sep) for the treatment of sexual dysunfction |
| 04/23/2003 | EP1303600A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 04/23/2003 | EP1303599A2 Methylated nucleotide regulation of upa gene expression |
| 04/23/2003 | EP1303588A2 Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue |
| 04/23/2003 | EP1303528A1 Adenosine compound and pharmaceutical composition containing the same |